XFOR (X4 Pharmaceuticals) Total Stockholders Equity: $168.45 Mil (As of Mar. 2026)


XFOR X4 Pharmaceuticals Inc XFOR
24 GF Score
Price $4.41
! 5 Warning Signs
View Full Analysis

What is X4 Pharmaceuticals Total Stockholders Equity?

X4 Pharmaceuticals XFOR +11.65% 24 Total Stockholders Equity is $168.45 Mil as of Mar. 2026. GuruFocus rates XFOR with a GF Score™ of 24/100. The stock has 5 warning signs investors should review.

X4 Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $168.45 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. X4 Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2026 was $1.79. The ratio of a company's debt over equity can be used to measure how leveraged this company is. X4 Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.46.

X4 Pharmaceuticals  (NAS:XFOR) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

X4 Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(168.45-0)/94.320
=1.79

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

X4 Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.733 + 76.52) / 168.45
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

X4 Pharmaceuticals Total Stockholders Equity Related Terms

X4 Pharmaceuticals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for X4 Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

X4 Pharmaceuticals Total Stockholders Equity Chart

X4 Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.41 74.05 51.10 22.15 186.29

X4 Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.94 3.97 61.62 186.29 168.45
XFOR
24GF Score
X4 Pharmaceuticals Inc XFOR
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $168.45 Mil mean?
X4 Pharmaceuticals (XFOR) has a Total Stockholders Equity of $168.45 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for X4 Pharmaceuticals and its competitors.
Is X4 Pharmaceuticals' Total Stockholders Equity too high?
X4 Pharmaceuticals' current Total Stockholders Equity is $168.45 Mil. Overall, X4 Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does X4 Pharmaceuticals' Total Stockholders Equity compare to CMPX and LRMR?
X4 Pharmaceuticals' Total Stockholders Equity of $168.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for X4 Pharmaceuticals and its competitors. X4 Pharmaceuticals's current Total Stockholders Equity is $168.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X4 Pharmaceuticals stock overvalued right now?
X4 Pharmaceuticals (XFOR) has a current Total Stockholders Equity of $168.45 Mil. The current Total Stockholders Equity is $168.45 Mil. X4 Pharmaceuticals' overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For X4 Pharmaceuticals (XFOR), the current Total Stockholders Equity is $168.45 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

X4 Pharmaceuticals Business Description

Address 61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
24GF Score

Get the complete analysis for XFOR

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.41
Price